【长春高新：子公司GenSci161注射液境内生产药品注册临床试验申请获受理】长春高新8月31日公告，近日，公司控股子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GenSci161注射液的境内生产药品注册临床试验申请获得受理。GenSci161注射液是金赛药业自主研发的一款治疗用生物制品1类药物，拟用于治疗结缔组织病相关间质性肺疾病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.